China Regenerative Medicine International Limited (HKG:8158)
Hong Kong · Delayed Price · Currency is HKD 0.5200
-0.0300 (-5.45%)
Jul 25, 2025, 2:19 PM HKT
HKG:8158 Income Statement
Financials in millions HKD. Fiscal year is January - December.
Millions HKD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| 90.62 | 69.49 | 41.54 | 282.9 | 182.14 | Upgrade | |
Revenue Growth (YoY) | 30.41% | 67.29% | -85.32% | 55.32% | 840.54% | Upgrade |
Cost of Revenue | 32.96 | 50.06 | 3.91 | 215.17 | 140.33 | Upgrade |
Gross Profit | 57.65 | 19.42 | 37.62 | 67.73 | 41.81 | Upgrade |
Selling, General & Admin | 51.52 | 45.54 | 25.82 | 47.45 | 46.95 | Upgrade |
Operating Expenses | 51.52 | 45.54 | 25.82 | 6.09 | 47.61 | Upgrade |
Operating Income | 6.14 | -26.11 | 11.81 | 61.63 | -5.8 | Upgrade |
Interest Expense | -1.13 | -0.98 | -0.78 | -0.74 | -17.91 | Upgrade |
Interest & Investment Income | 17.58 | 0.01 | 0 | 0.01 | 0.02 | Upgrade |
Other Non Operating Income (Expenses) | -4.87 | -80.66 | -3.67 | -1.67 | -25.18 | Upgrade |
EBT Excluding Unusual Items | 17.72 | -107.74 | 7.35 | 59.24 | -48.86 | Upgrade |
Gain (Loss) on Sale of Investments | - | - | - | - | 2.34 | Upgrade |
Other Unusual Items | 0.04 | 0.04 | 0.91 | 5.05 | -95.58 | Upgrade |
Pretax Income | 17.75 | -107.7 | 8.27 | 64.29 | -142.1 | Upgrade |
Income Tax Expense | - | - | 3.71 | 12.47 | 12.38 | Upgrade |
Earnings From Continuing Operations | 17.75 | -107.7 | 4.56 | 51.83 | -154.48 | Upgrade |
Earnings From Discontinued Operations | - | - | - | - | -284.35 | Upgrade |
Net Income to Company | 17.75 | -107.7 | 4.56 | 51.83 | -438.83 | Upgrade |
Minority Interest in Earnings | - | - | - | - | 34.6 | Upgrade |
Net Income | 17.75 | -107.7 | 4.56 | 51.83 | -404.23 | Upgrade |
Net Income to Common | 17.75 | -107.7 | 4.56 | 51.83 | -404.23 | Upgrade |
Net Income Growth | - | - | -91.21% | - | - | Upgrade |
Shares Outstanding (Basic) | 304 | 286 | 285 | 285 | 161 | Upgrade |
Shares Outstanding (Diluted) | 304 | 286 | 285 | 285 | 161 | Upgrade |
Shares Change (YoY) | 6.23% | 0.34% | - | 77.64% | 82.73% | Upgrade |
EPS (Basic) | 0.06 | -0.38 | 0.02 | 0.18 | -2.52 | Upgrade |
EPS (Diluted) | 0.06 | -0.38 | 0.02 | 0.18 | -2.52 | Upgrade |
EPS Growth | - | - | -91.21% | - | - | Upgrade |
Free Cash Flow | 17.68 | 10.52 | -15.03 | -3.83 | -399.15 | Upgrade |
Free Cash Flow Per Share | 0.06 | 0.04 | -0.05 | -0.01 | -2.48 | Upgrade |
Gross Margin | 63.62% | 27.95% | 90.58% | 23.94% | 22.95% | Upgrade |
Operating Margin | 6.77% | -37.58% | 28.42% | 21.79% | -3.19% | Upgrade |
Profit Margin | 19.59% | -154.99% | 10.97% | 18.32% | -221.94% | Upgrade |
Free Cash Flow Margin | 19.51% | 15.13% | -36.17% | -1.35% | -219.15% | Upgrade |
EBITDA | 6.8 | -25.54 | 11.98 | 61.71 | -4.07 | Upgrade |
EBITDA Margin | 7.50% | -36.75% | 28.83% | 21.81% | -2.24% | Upgrade |
D&A For EBITDA | 0.66 | 0.57 | 0.17 | 0.08 | 1.73 | Upgrade |
EBIT | 6.14 | -26.11 | 11.81 | 61.63 | -5.8 | Upgrade |
EBIT Margin | 6.77% | -37.58% | 28.42% | 21.79% | -3.19% | Upgrade |
Effective Tax Rate | - | - | 44.90% | 19.39% | - | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.